ABSTRACT
Background Outpatient surgery has been shown safe and effective for anterior cervical discectomy and fusion (ACDF), and more recently, for 1-level cervical disc arthroplasty (CDA). The purpose of this analysis is to compare the safety and efficiency of 1-level and 2-level CDA performed in an ambulatory surgery center (ASC) and in a hospital setting.
Methods The study was a retrospective collection and analysis of data from consecutive CDA patients treated in ASCs compared to a historical control group of patients treated in hospital settings who were classified as outpatient (0 or 1-night stay) or inpatient (2 or more nights). Surgery time, blood loss, return to work, adverse events (AEs), and subsequent surgeries were compared.
Results The sample consisted of 145 ASC patients, 348 hospital outpatients, and 65 hospital inpatients. A greater proportion of 2-level surgeries were performed in hospital than ASC. Surgery times were significantly shorter in ASCs than outpatient or inpatient 1-level (63.6 ± 21.6, 86.5 ± 35.8, and 116.7 ± 48.4 minutes, respectively) and 2-level (92.4 ± 37.3, 126.7 ± 43.8, and 140.3 ± 54.5 minutes, respectively) surgeries. Estimated blood loss was also significantly less in ASC than outpatient and inpatient 1-level (18.5 ± 30.6, 43.7 ± 35.9, and 85.7 ± 98.0 mL, respectively) and 2-level (21.1 ± 12.3, 67.8 ± 94.9, and 64.9 ± 66.1 mL). There were no hospital admissions and no subsequent surgeries among ASC patients. ASC patients had 1 AE (0.7%) and hospital patients had 10 AEs (2.4%). Working patients returned to work after a similar number of days off, but fewer ASC patients had returned to work by the end of the 90-day period.
Conclusions Both 1- and 2-level CDA may be performed safely in an ASC. Surgeries in ASCs are of shorter duration and performed with less blood loss without increased AEs.
Footnotes
Disclosures and COI: The device manufacturer, Zimmer Biomet (formerly LDR Spine), sponsored the Mobi-C Cervical Disc ASC Study. Zimmer Biomet contributed to the design and conduct of the study, and provided assistance with analysis of data and manuscript review. The authors also report receiving writing or editorial assistance for this paper from Zimmer Biomet. These authors report the following potential or perceived conflicts: M.F. Gornet reports consulting for Aesculap and Medtronic; stockownership of Bonovo, International Spine & Orthopedic Institute, LLC, Nocimed, OuroBoros, Paradigm Spine; and royalties from Medtronic and RTI. R. Kube reports research support from Zimmer Biomet and consulting for Paradigm Spine. R. Sherban reports consulting for Zimmer Biomet. N.J. Wills reports consulting for Zimmer Biomet and Medtronic. F.W. Schranck reports stockownership: Nocimed.
- ©International Society for the Advancement of Spine Surgery